Artivion (AORT) announced that the U.S. FDA has granted a Humanitarian Device Exemption for use of the AMDS Hybrid Prosthesis in acute DeBakey Type I dissections in the presence of malperfusion. The AMDS is the world’s first aortic arch remodeling device for use in the treatment of acute DeBakey Type I aortic dissections.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AORT:
- Artivion price target raised to $35 from $32 at Lake Street
- Artivion price target raised to $32 from $29.60 at Ladenburg
- Artivion’s Q3 2024: Revenue Growth and Strategic Progress
- Artivion narrows 2024 revenue view to $389M-$396M from $388M-$396M
- Artivion reports Q3 non-GAAP EPS 12c, consensus (6c)